| Literature DB >> 24837132 |
Joost P G Sluijter1, Gianluigi Condorelli2, Sean M Davidson3, Felix B Engel4, Peter Ferdinandy5, Derek J Hausenloy6, Sandrine Lecour6, Rosalinda Madonna7, Michel Ovize8, Marisol Ruiz-Meana9, Rainer Schulz10, Linda W Van Laake11.
Abstract
The morbidity and mortality from ischemic heart disease (IHD) remain significant worldwide. The treatment for acute myocardial infarction has improved over the past decades, including early reperfusion of occluded coronary arteries. Although it is essential to re-open the artery as soon as possible, paradoxically this leads to additional myocardial injury, called acute ischemia-reperfusion injury (IRI), for which currently no effective therapy is available. Therefore, novel therapeutic strategies are required to protect the heart from acute IRI in order to reduce myocardial infarction size, preserve cardiac function and improve clinical outcomes in patients with IHD. In this review article, we will first outline the pathophysiology of acute IRI and review promising therapeutic strategies for cardioprotection. These include novel aspects of mitochondrial function, epigenetics, circadian clocks, the immune system, microvesicles, growth factors, stem cell therapy and gene therapy. We discuss the therapeutic potential of these novel cardioprotective strategies in terms of pharmacological targeting and clinical application.Entities:
Keywords: Cardioprotection; Circadian clock; Growth factors; Ischemia–reperfusion injury; Microvesicles; Mitochondria
Mesh：
Substances：
Year: 2014 PMID： 24837132 DOI： 10.1016/j.pharmthera.2014.05.005
Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310